• Carbon Black

  Participated · Equity · Apr 2011

  Bit9 (Bit9 + Carbon Black) is a Waltham, MA-based provider of a next-generation endpoint security platform led by Patrick Morley. The platform is designed to prevent, detect and respond to advanced threats that target users, servers and fixed-function devices. The company serves almost 2,000 customers worldwide. Bit9 closed a $54.5M Series F funding round in October 2015. The company intends to use the funds to accelerate growth, drive product innovation and support international expansion. The article describes participation from both existing and new investors in the round. Carbon Black develops endpoint-focused security software that it describes as a “surveillance camera” for computers, collecting and retaining telemetry for security and business intelligence. The company launched “Carbon Black 3.0,” a lightweight, scalable 9-in-1 solution that offers enterprise-wide visibility and historical traceability. The product is intended to speed breach investigation and incident response by providing answers in seconds, even for events that occurred months earlier. Carbon Black 3.0 bundles capabilities including malware detection, incident response, vulnerability assessment, patch management, file and registry integrity monitoring, policy enforcement, license management, and new-application notification. The platform is positioned to reduce incident response costs and inform overall technology‑health decisions for security and business teams. Carbon Black was established in 2011 as a subsidiary of Kyrus and is presented in the article from New York. Bit9 builds cybersecurity software that enforces a whitelist of trusted applications and sites rather than relying on blacklists of known threats. The company says it works with 30 of the Fortune 100 and about 700 organizations in total, and reports 100% annual business growth. CEO Patrick Morley highlights that Bit9’s approach stopped the Flame virus and halted the RSA breach. Bit9 plans to extend its whitelist coverage to more platforms, including mobile, bring‑your‑own‑device and cloud environments, with some developments expected in the next two quarters. Financially, the company recently closed a $34.5M Series D and has raised $72.8M to date. Bit9 positions its product to address rising organized cybercrime, nation‑state attacks and hacktivism that have pushed cybersecurity conversations to the board level. Bit9 provides advanced endpoint protection, using application whitelisting and the Bit9 Global Software Registry to identify and control software allowed to run on endpoints. Its solutions aim to eliminate risks from modern malware, targeted attacks and Advanced Persistent Threats by giving IT teams visibility and control over endpoint software. Bit9's customers span government, financial services, retail, healthcare, e-commerce and education, and the company reported triple-digit revenue growth in 2010, including 60% growth in new customer acquisition. The company also reported a doubling of revenue from the channel and that 30% of sales came from existing customers. Bit9 plans to use new funding to invest in product development, expand across Europe and ramp up sales and marketing. Privately held and based in Waltham, Massachusetts, Bit9 traces core research to a $2M NIST ATP grant awarded in 2003 that underpins its application whitelisting technology.

• Recyclebank

  Participated · Series C · Feb 2011

  Recycle Rewards operates through its subsidiary Recyclebank, which offers a rewards-for-recycling program in more than 300 communities across the United States and the U.K. The program partners with more than 3,000 local and national businesses to provide incentives for green actions. Recyclebank also manages social and gaming properties—including Greenopolis.com, RecyclePix, and the Oceanopolis Facebook game—to drive real-world recycling via social engagement. The company will incorporate Waste Management’s Greenopolis web-based rewards catalog into its existing rewards program to expand incentives for members. Leadership noted in the articles includes CEO Jonathan Hsu for Recyclebank; Waste Management is led by president and CEO David Steiner. The deal is positioned to increase growth prospects and broaden reach to new customers through a strategic partnership with Waste Management. Recyclebank operates an online green-action platform that incentivizes recycling, reusing and reduced energy usage by awarding points redeemable for discounts and rewards. The company partners with municipalities, haulers, small businesses and corporate brands to drive participation. Led by CEO Jonathan Hsu and based in New York City, Recyclebank uses its platform to motivate collective environmental impact. It closed a $14M extension to its Series C financing, bringing the total Series C to $47M. Recyclebank intends to use the new funds for product development, enhancements to its online platform, and expansion into new communities and areas of sustainability. RecycleBank operates a rewards-for-recycling program that partners with municipalities, waste haulers, and marketers to increase household recycling rates. The service awards RecycleBank Dollars to participating households, which can be redeemed with a network of over 300 reward partners. The company emphasizes close relationships with waste disposal companies and currently has partnerships with several haulers. Reported household adoption in communities where RecycleBank is instituted averages 80–90 percent. RecycleBank is expanding its list of retail partners (including Whole Foods and Coke) and plans further market expansion to broaden advertising appeal. The recent funding is positioned to support these expansion plans and broaden consumer access in more markets.

• Tethys BioScience

  Participated · Series D · Jul 2010

  Tethys Bioscience develops the Tethys PreDx™ Diabetes Risk Score (DRS), a multimarker blood test that identifies patients at high risk of developing type 2 diabetes within five years. The test is designed to pinpoint the 10–20% of individuals at the highest near-term risk to help target intervention. The company raised new capital to support expanded commercialization of the PreDx DRS. The financing comprised both venture capital and a working capital loan, bringing additional resources to its Series D. Following the latest financings, the company’s Series D has reached a total of $48M. The company is based in Emeryville, California. Tethys Bioscience, based in Emeryville, CA, develops blood tests to support identification of chronic diseases, with a focus on diabetes. Its core product is the PreDx™ Diabetes Risk Score (DRS), a blood test that helps clinicians identify patients at highest risk of developing type 2 diabetes within five years. The company has secured external financing to support commercialisation of the PreDx DRS. Tethys closed a $25M Series D to advance its go-to-market efforts for the product. As part of the financing, an investor representative joined the company’s board, indicating investor engagement in governance.

• P3D

  Led · Equity · Jan 2010

  P3D (Phase III Development Company S.A.R.L.) was recently established to assist pharmaceutical companies in managing and funding Phase III clinical trials in the European Union. Its primary role is to fund and manage late‑stage clinical development, initially focusing on label expansion of an already approved therapeutic under a deal with a major global pharmaceutical company. Under that agreement P3D will support Phase III trials in additional indications and, in return, will receive development and regulatory milestone payments, a share of certain out‑licensed royalties, and a percentage of product revenue if approved in those indications. Paul Capital Healthcare has committed up to $100M in initial funding to P3D. The structure positions P3D to participate in a diversified pool of royalties, milestones and revenue interests tied to late‑stage development programs. No operating metrics (revenue/users) or detailed financing instruments were disclosed in the announcement.

No current team members are available.